Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.48 |
| ▸ | MET | P08581 | 10/20 | 0.42 |
| ▸ | FLT3 | P36888 | 5/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | MST1R | Q04912 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135108 | 0.88 | TLR8 (0.57) | TLR8IRAK4 | |
| Hydrochloric Acid SCHEMBL30508248 | 0.87 | TLR8 (0.56) | TLR8IRAK4 | |
| Hydrochloric Acid SCHEMBL28215605 | 0.87 | TLR8 (0.56) | TLR8IRAK4 | |
| SCHEMBL30508251 | 0.80 | TLR8 (0.49) | TLR8IRAK4MET | |
| SCHEMBL30508196 | 0.80 | TLR8 (0.49) | TLR8IRAK4MET | |
| Hydrochloric Acid SCHEMBL30508246 | 0.79 | TLR8 (0.48) | TLR8IRAK4MET | |
| SCHEMBL11890643 | 0.78 | TLR8 (0.44) | TLR8IRAK4BACE1 | |
| SCHEMBL25265242 | 0.78 | ATM (0.45) | TLR8IRAK4 | |
| SCHEMBL25191308 | 0.78 | ATM (0.45) | TLR8IRAK4 | |
| SCHEMBL29082025 | 0.78 | TLR8 (0.48) | TLR8IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | TLR8 4018/4885IRAK4 3781/4885MET 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.